5月27日,恒瑞医药与美国Kailera Therapeutics公司共同宣布:其口服小分子GLP-1受体激动剂HRS-7535在中国284名成人2型糖尿病受试者中开展的Ⅲ期临床试验OUTSTAND-1取得积极顶线结果。 32周主要终点数据显示,HRS-7535三个剂量组(30mg、60mg、90mg)HbA1c降幅达1.40%至1.68%,关键次要终点HbA1c<7.0%的达标率达83.5%至...
Source Link5月27日,恒瑞医药与美国Kailera Therapeutics公司共同宣布:其口服小分子GLP-1受体激动剂HRS-7535在中国284名成人2型糖尿病受试者中开展的Ⅲ期临床试验OUTSTAND-1取得积极顶线结果。 32周主要终点数据显示,HRS-7535三个剂量组(30mg、60mg、90mg)HbA1c降幅达1.40%至1.68%,关键次要终点HbA1c<7.0%的达标率达83.5%至...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.